Impact of sustained virologic response on chronic kidney disease progression in hepatitis C

Elizabeth S. Aby, Tien S. Dong, Jenna Kawamoto, Joseph R. Pisegna, Jihane N. Benhammou

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

AIM To determine how sustained virological response at 12 wk (SVR12) with direct acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection affects chronic kidney disease (CKD) progression. METHODS A retrospective analysis was performed in patients aged ≥ 18 years treated for HCV with DAAs at the VA Greater Los Angeles Healthcare System from 2014-2016. The treatment group was compared to patients with HCV from 2011-2013 who did not undergo HCV treatment, prior to the introduction of DAAs; the control group was matched to the study group in terms of age, gender, and ethnicity. Analysis of variance and co-variance was performed to compare means between SVR12 subgroups adjusting for co-variates. RESULTS Five hundred and twenty-three patients were evaluated. When comparing the rate of change in estimated glomerular filtration rate (eGFR) one-year after HCV treatment to one-year before treatment, patients who achieved SVR12 had a decline in GFR of 3.1 mL/min ± 0.75 mL/min per 1.73 m2 compared to a decline in eGFR 11.0 mL/min ± 2.81 mL/min per 1.73 m2 in patients who did not achieve SVR12 (P = 0.002). There were no significant clinical differences between patients who achieved SVR12 compared to those who did not in terms of cirrhosis, treatment course, treatment experience, CKD stage prior to treatment, diuretic use or other co-morbidities. The decline in eGFR in those with untreated HCV over 2 years was 2.8 mL/min ± 1.0 mL/min per 1.73 m2, which was not significantly different from the eGFR decline noted in HCV-treated patients who achieved SVR12 (P = 0.43). CONCLUSION Patients who achieve SVR12 have a lesser decline in renal function, but viral eradication in itself may not be associated improvement in renal disease progression.

Original languageEnglish (US)
Pages (from-to)1352-1360
Number of pages9
JournalWorld Journal of Hepatology
Volume9
Issue number36
DOIs
StatePublished - Dec 28 2017

Bibliographical note

Funding Information:
Supported by Department of Veterans Affairs RR and D Merit Review, No. I01 RX000194 (to Pisegna JR); Human Studies CORE through CURE: Digestive Diseases Research Center supported by NIH grant; Nos. P30DK41301 (to Pisegna JR) and NIH T32 DK07180-43 (to Benhammou JN).

Publisher Copyright:
© The Author(s) 2017.

Keywords

  • Chronic kidney disease
  • Direct-acting antivirals
  • End stage renal disease
  • Hepatitis C
  • Sustained virological response

Fingerprint

Dive into the research topics of 'Impact of sustained virologic response on chronic kidney disease progression in hepatitis C'. Together they form a unique fingerprint.

Cite this